Mostrando 1 - 4 Resultados de 4 Para Buscar 'Carrilho, Flair', tiempo de consulta: 0.01s Limitar resultados
1
artículo
PIB: A score to select sorafenib treatment candidates for hepatocellular carcinoma in resource-limited settings.
Publicado por
Diaz-Ferrer, Javier, Leathers, James S., Balderramo, Domingo, Prieto, Jhon, Diehl, Fernando, Gonzalez-Ballerga, Esteban, Ferreiro, Melina R., Carrera, Enrique, Barreyro, Fernando, Singh, Dupinder, Mattos, Angelo Z., Carrilho, Flair, Debes, José D.
Publicado 2018 Enlace
El Carcinoma Hepatocelular es la segunda causa de muerte relacionada con cáncer en el mundo. Sorafenib, un inhibidor de tirosina quinasa, permanece en el estandar de la prescripción a pacientes con carcinoma hepatocelular avanzado o inoperable. Usando información de la red de investigación en hígado en Sud América (1336 casos de carcinoma hepatocelular) se creó un sistema de pronóstico costo-efectividad para ayudar a identificar a los pacientes con probabilidad del beneficio de sobrevivencia con el tratamiento con sorafenib.
Agregar a favoritos
Guardado en:
3
artículo
Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population
Publicado por
Zambrano-Huailla, Rommel, Guedes, Laura, Stefano, Jose Tadeu, de Souza, Arthur A. Arrais, Marciano, Sebastián, Yvamoto, Erika, Michalczuk, Matheus Truccolo, Vanni, Denise Siqueira, Rodriguez, Hernan, Carrilho, Flair Jose, Alvares-da-Silva, Mario Reis, Gadano, Adrian, Arrese, Marco, Miranda, Adelina Lozano, Oliveira, Claudia P.
Publicado 2020 Enlace
Introduction and aims Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results The distributi...
Agregar a favoritos
Guardado en:
4
artículo
Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America
Publicado por
Farias, Alberto Queiroz, Vilalta, Anna Curto, Zitelli, Patrícia Momoyo, Pereira, Gustavo, Goncalves, Luciana L., Torre, Aldo, Diaz, Juan Manuel, Gadano, Adrian C., Mattos, Angelo Z., Mendes, Liliana S.C., Alvares-da-Silva, Mario R., Bittencourt, Paulo L., Benitez, Carlos, Couto, Claudia Alves, Mendizabal, Manuel, Toledo, Claudio L., Mazo, Daniel F., Barradas, Mauricio Castillo, Uson Raposo, Eva M., Padilla-Machaca, P. Martín, Lozano Miranda, Adelina Zarela, Malé-Velázquez, René, Lyra, André Castro, Dávalos-Moscol, Milagros B., Pérez Hernandez, Jose L, Ximenes, Rafael O., Silva, Giovanni Faria, Beltrán-Galvis, Oscar A., González Huezo, María S., Bessone, Fernando, Rocha, Tarciso D.S., Fassio, Eduardo, Terra, Carlos, Marín, Juan I., Casas, Patricia Sierra, Peña-Ramirez, Carlos de la, Parera, Ferran Aguilar, Fernandes, Flavia, da Penha Zago-Gomes, Maria, Méndez-Guerrero, Osvely, Marciano, Sebastián, Mattos, Angelo A., Oliveira, Joao C., Guerreiro, Gabriel T.S., Codes, Liana, Arrese, Marco, Nardelli, Mateus J., Silva, Marcelo O., Palma-Fernandez, Renato, Alcantara, Camila, Garrido, Cristina Sánchez, Trebicka, Jonel, Gustot, Thierry, Fernández, Javier, Clària, Joan, Jalan, Rajiv, Angeli, Paolo, Arroyo, Vicente, Moreau, Richard, Carrilho, Flair J.
Publicado 2023 Enlace
BACKGROUND & AIMS: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (e.g., Covid-19). This study aimed to investigate the association of genetic ancestry and race with acute-onchronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure and high risk of short-term death. METHODS: This prospective cohort study analyzed a comprehensive set of data including genetic ancestry and race, among several others, in 1274 patients with acutely decompensated cirrhosis (ADC) who were nonelectively admitted to 44 hospitals from 7 Latin American countries. RESULTS: 395 (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4%...
Agregar a favoritos
Guardado en: